Fundraising Fox
Dunad
Cambridge, GB · Founded 2020 · 12 employees on LinkedIn · 3 known investors
Find your way into Dunad
Sign up to see every warm intro you have to Dunad
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Dunad team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.
Founders & leadership
PH
Pearl HuangPresident & CEOPearl Huang is President and CEO of Dunad Therapeutics, a biotech company developing oral small-molecule medicines for neurodegenerative diseases. She holds an S.B. in Life Sciences from MIT and a Ph.D. in Molecular Biology from Princeton University, and serves as an Independent Director at Waters and Non-Executive Director at BB Biotech.
SH
Stephen HuhnCMO
Investors · 3
Frequently asked questions
- What does Dunad do?
- Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.
- Who are Dunad's investors?
- Dunad's investors include BGV, Alpha Wave Global, Epidarex Capital.
- Where is Dunad headquartered?
- Dunad is headquartered in Cambridge, GB.